Page last updated at 23:58 GMT, Wednesday, 31 December 2008

Test could offer lung cancer clue

lung cancer
Lung cancer patients do better if their disease is detected early

Testing a lung cancer patient's blood could help doctors predict the likely success of chemotherapy treatment.

UK scientists identified a molecule made by a more aggressive form of the disease, the journal Clinical Cancer Research reported.

Patients with this in their blood were less likely to respond to drugs, they said.

Cancer Research UK said the discovery could help doctors choose the right kind of treatment for patients.

Lung cancer kills more than 30,000 people in the UK every year, and survival rates have not improved alongside those for breast or bowel cancer in recent years.

This discovery is an important step to understanding how to treat lung cancer patients more effectively
Lesley Walker
Cancer Research UK

There is more than one type of lung cancer, but the variety under investigation by Liverpool-based researchers, small-cell lung cancer, which accounts for between 15% and 20% of cases, is one of the more difficult to treat.

Even small cell lung cancer comes in different forms, with a version called "neuroendocrine" being the least likely to be treated successfully.

The researchers found that a molecule called SCG3 mRNA was more likely to be found in the blood of people with neuroendocrine small cell cancer.

In theory, if larger studies back this up, it could mean that patients arriving at the clinic could be tested to give doctors an idea of the likely success of therapy - or perhaps to predict when a patient was relapsing before other signs emerged.

No tests

It might also make it easier for scientists, when looking at new chemotherapy treatments in trials, to compare their effectiveness in different groups of small cell lung cancer patients.

Dr Judy Coulson, from the University of Liverpool, said: "There are currently no blood-based markers routinely used to monitor patients with this type of lung cancer.

"We found that SCG3 mRNA is an incredibly sensitive marker of these tumours and could be used to detect circulating tumour cells in patients with this disease."

Lesley Walker, from Cancer Research UK, said: "This discovery is an important step to understanding how to treat lung cancer patients more effectively.

"Lung cancer can be very difficult to treat in its later stages, either because it has spread or because there are too many tumours."



Print Sponsor


SEE ALSO
Gene 'roadmap' for lung cancers
22 Oct 08 |  Health

RELATED INTERNET LINKS
The BBC is not responsible for the content of external internet sites


FEATURES, VIEWS, ANALYSIS
Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit

BBC navigation

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.

Americas Africa Europe Middle East South Asia Asia Pacific